Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd + Nivolumab + Chemotherapy in HER2-Low Gastric/GEJ Adenocarcinoma
NCT07529613Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by National Cancer Center Hospital East. Started Dec 2023; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07529613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529613.